We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

ddPCR Brings Confidence to Leukemia Monitoring

Article   Jan 03, 2019 | by Chinmay Sheth, Marketing Manager, Clinical Diagnostics at Bio-Rad Laboratories

 
Quantifying Minimal Residual Disease in Chronic Myeloid Leukemia

Droplet digital PCR is sensitive enough to detect rare DNA sequences such as BCR-ABL gene fusions. From left: the sample is partitioned into 20,000 nanoliter-sized droplets; each droplet undergoes PCR amplification to endpoint, and droplets that contain the target DNA fluoresce; positive droplets are counted to enable absolute and precise quantification of the target sequence.

 
 
 

RELATED ARTICLES

Uncovering the Secrets of the Breast Cancer Epigenome

Article

The epigenome plays a crucial role in the development of breast cancer. This exciting and rapidly evolving area of research holds great promise for new interventions – from prevention through to personalized treatment.

READ MORE

In the “Nick” of Time: Researchers Identify a Surprising Behaviour of CRISPR Nucleases

Article

In a recent academic collaboration, scientists discovered another surprising behavior of the Cas9 and Cpf1 enzymes – a behavior which may have implications when developing novel therapies with CRISPR. We spoke with Brett Robb, the Scientific Director for RNA and Genome Editing at New England Biolabs Inc, and Becky Fu (previously a graduate student at Stanford University and now a Postdoctoral fellow at UCSF) to learn more about their research.

READ MORE

Novel Clinical Mass Spectrometry Applications: From Bench to Bedside

Article

Mass spectrometry (MS) was once primarily within the chemist’s domain for molecular structural characterization. MS is now growing in familiarity and popularity for a variety of clinical applications; from laboratory tests for analyte quantification, to diagnostic applications in infectious disease, inborn errors of metabolism, and cancer, including a foray into the surgeon’s suite.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Cancer Research Drug Discovery Genomics Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE